Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019
September 16 2019 - 7:30AM
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel therapeutics to treat cystic fibrosis,
cystinosis, inherited retinal disorders and other diseases caused
by nonsense mutations limiting production of functional proteins,
today announced that Robert E. Ward, Chairman and Chief Executive
Officer of Eloxx, will make a presentation and host one-on-one
meetings with investors at the
2019 Cantor Global
Healthcare Conference on October 3rd, 2019 at the
InterContinental New York Barclay Hotel.
The presentation will be webcast live and may be
accessed by visiting the “Events & Presentations” page within
the Investors section of the Eloxx website at
http://investors.eloxxpharma.com or by using the link below. A
replay of the webcast will be available on the Eloxx website
following the conference.Date: Thursday, October
3, 2019Time: 4:10 P.M. ETWebcast:
http://wsw.com/webcast/cantor10/elox/
About Eloxx
PharmaceuticalsEloxx Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company developing novel
RNA-modulating drug candidates (designed to be eukaryotic ribosomal
selective glycosides) that are formulated to treat rare and
ultra-rare premature stop codon diseases. Premature stop codons are
point mutations that disrupt protein synthesis from messenger RNA.
As a consequence, patients with premature stop codon diseases have
reduced or eliminated protein production from the mutation bearing
allele accounting for some of the most severe phenotypes in these
genetic diseases. These premature stop codons have been identified
in over 1,800 rare and ultra-rare diseases.
Read-through therapeutic development is focused on extending
mRNA half-life and increasing protein synthesis by enabling the
cytoplasmic ribosome to read through premature stop codons to
produce full-length proteins. Eloxx’s lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to
restore production of full-length functional proteins. ELX-02 is in
the early stages of clinical development focusing on cystic
fibrosis and cystinosis. ELX-02 is an investigational drug that has
not been approved by any global regulatory body. Eloxx’s
preclinical candidate pool consists of a library of novel drug
candidates designed to be eukaryotic ribosomal selective glycosides
identified based on read-through potential. Eloxx recently
announced a new program focused on rare ocular genetic disorders.
Eloxx is headquartered in Waltham, MA, with R&D operations in
Rehovot, Israel. For more information, please visit
www.eloxxpharma.com.
Forward-Looking StatementsThis press
release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections,
and speak only as of the date they are made. We undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and
uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, including: the
development of the Company’s read-through technology; the approval
of the Company’s patent applications; the Company’s ability to
successfully defend its intellectual property or obtain necessary
licenses at a cost acceptable to the Company, if at all; the
successful implementation of the Company’s research and development
programs and collaborations; the Company’s ability to obtain
applicable regulatory approvals for its current and future product
candidates; the acceptance by the market of the Company’s products
should they receive regulatory approval; the timing and success of
the Company’s preliminary studies, preclinical research, clinical
trials, and related regulatory filings; the ability of the Company
to consummate additional financings as needed; as well as those
discussed in more detail in our Annual Report on Form 10-K and our
other reports filed with the Securities and Exchange
Commission.
Contact:
Barbara Ryan 203-274-2825
barbarar@eloxxpharma.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Sep 2023 to Sep 2024